Dash Bio has raised a $30 million Series A round led by Oak HC/FT, with participation from Freestyle Capital and Swift Ventures, bringing its total funding to $47.5 million. The company, founded in 2024 by former Moderna chief data & AI officer Dave Johnson, operates a 24,000-square-foot GLP-compliant lab in Waltham, Massachusetts, focusing on automated bioanalysis for preclinical and clinical drug development. Dash Bio now serves more than 30 drug developers, including four top 15 global pharmaceutical companies, and plans to expand its assay modalities and service offerings across the drug development value chain. Sources: Dash Bio nets $30M for 'Amazon Web Services of drug ... Ariel Winton-Jones' Post Andrew Dunn's Post Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvicto Unblocking the Drug Development Bottlenecks: Why We're ... Dash Bio raises $30 Million Venture Series Unknown ... Dash Bio $30M Series B Fun...
- Get link
- X
- Other Apps